---
title: "CING.US (CING.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CING.US/news.md"
symbol: "CING.US"
name: "CING.US"
parent: "https://longbridge.com/en/quote/CING.US.md"
datetime: "2026-06-13T21:06:39.405Z"
locales:
  - [en](https://longbridge.com/en/quote/CING.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CING.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CING.US/news.md)
---

# CING.US (CING.US) — Related News

### [Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday](https://longbridge.com/en/news/289067628.md)
*2026-06-08T13:52:34.000Z*
> Wall Street analysts updated price targets for several stocks. BTIG raised Oncology Institute's target to $8, while Pipe

### [Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN](https://longbridge.com/en/news/288878717.md)
*2026-06-05T14:32:23.000Z*
> This week, the biotech sector saw FDA approvals for Philips' AI ultrasound and Lupin's oncology/ophthalmology drugs, whi

### [Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 | CING Stock News](https://longbridge.com/en/news/288772438.md)
*2026-06-04T12:50:37.000Z*
> Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 | CING Stock News

### [Top Biotech Gainers: ABVX, CING, DRTS, MMED...](https://longbridge.com/en/news/288656169.md)
*2026-06-04T02:42:22.000Z*
> Top biotech gainers included ABVX (+24.3%), driven by positive Phase 3 ulcerative colitis trial results for Obefazimod; 

### [Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL](https://longbridge.com/en/news/288507972.md)
*2026-06-03T02:45:30.000Z*
> Top biotech gainers included Bluejay Diagnostics (BJDX), which surged 100% on a strategic partnership with Argonaut and 

### [<![CDATA[Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301]]>](https://longbridge.com/en/news/288468860.md)
*2026-06-02T18:51:15.000Z*
> The FDA accepted a new drug application for giredestrant, an oral SERD for breast cancer, granting priority review with